These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 39058274)

  • 1. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
    Saglietto A; Falasconi G; Penela D; Francia P; Sau A; Ng FS; Dusi V; Castagno D; Gaita F; Berruezo A; De Ferrari GM; Anselmino M
    Eur J Clin Invest; 2024 Jul; ():e14292. PubMed ID: 39058274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.
    Zhang HD; Ding L; Liu K; Mi LJ; Zhang AK; Yu FY; Yan XX; Peng FH; Shen YJ; Tang M
    Diabetes Metab Syndr; 2024 Jun; 18(6):103067. PubMed ID: 38955095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials.
    Wu S; Lu W; Chen Z; Dai Y; Chen K; Zhang S
    Diabetol Metab Syndr; 2022 Dec; 14(1):195. PubMed ID: 36572913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
    Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
    Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
    Xie Z; Hu J; Gu H; Li M; Chen J
    Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
    Alhindi Y; Avery A
    Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Moiz A; Levett JY; Filion KB; Peri K; Reynier P; Eisenberg MJ
    Am J Cardiol; 2024 Jul; 222():121-130. PubMed ID: 38679221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
    Nauck MA; Quast DR
    Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Shi FH; Li H; Cui M; Zhang ZL; Gu ZC; Liu XY
    Front Pharmacol; 2018; 9():576. PubMed ID: 29915538
    [No Abstract]   [Full Text] [Related]  

  • 14. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Banerjee M; Pal R; Mukhopadhyay S; Nair K
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Karagiannis T; Malandris K; Avgerinos I; Stamati A; Kakotrichi P; Liakos A; Vasilakou D; Kakaletsis N; Tsapas A; Bekiari E
    Diabetologia; 2024 Jul; 67(7):1206-1222. PubMed ID: 38613667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.
    Wu W; Tong HM; Li YS; Cui J
    Endocrine; 2024 Mar; 83(3):571-584. PubMed ID: 38097902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.